Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | GLA | P06280 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | APEX1 | P27695 | 1/20 | 0.31 |
| ▸ | RECQL | P46063 | 1/20 | 0.31 |
| ▸ | BLM | P54132 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5062914 | 0.81 | KDM4E (0.32) | KDM4EALDH1A1GLAGAAHPGD | |
| SCHEMBL9936008 | 0.81 | KDM4E (0.32) | KDM4EALDH1A1GLAGAAHPGD | |
| Hydrochloric Acid SCHEMBL21174542 | 0.79 | KDM4E (0.32) | KDM4EALDH1A1GLAGAAHPGD | |
| SCHEMBL6948806 | 0.78 | JAK2 (0.32) | KDM4EALDH1A1GLAGAAHPGD | |
| SCHEMBL11066168 | 0.78 | PDK2 (0.35) | KDM4EALDH1A1GLAGAAHPGD | |
| SCHEMBL23409493 | 0.78 | HTT (0.39) | HSD17B10 | |
| SCHEMBL30842861 | 0.78 | HTT (0.39) | HSD17B10 | |
| SCHEMBL1797752 | 0.78 | — | — | |
| SCHEMBL7420623 | 0.77 | PARP1 (0.30) | KDM4EALDH1A1GLAGAAHPGD | |
| SCHEMBL6006918 | 0.74 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3510404-A1 | CHEMICAL PROBES OF LYSYL OXIDASE-LIKE 2 AND USES THEREOF | Pharmakea, Inc. (US) | 2019-07-17 | — | — | EP | claimed |
| US-20190192697-A1 | CHEMICAL PROBES OF LYSYL OXIDASK-LIKE 2 AND USES THEREOF | PHARMAKEA, INC. | 2019-06-27 | — | — | US | claimed |
| WO-2018048928-A1 | CHEMICAL PROBES OF LYSYL OXIDASE-LIKE 2 AND USES THEREOF | PHARMAKEA, INC. (US) | 2018-03-15 | — | — | WO | claimed |
| CN-111132721-B | Multiple-inflation type intravascular medical device | W.L.戈尔及同仁股份有限公司 | 2022-07-19 | — | — | CN | disclosed |
| CN-109689692-B | Bispecific antibodies and antibody conjugates for tumor therapy and uses thereof | 本康生物制药（深圳）有限公司 | 2021-11-12 | — | — | CN | disclosed |
| CN-110651996-A | Food for nourishing and improving kidney function and preparation method thereof | 马晨光 | 2020-01-07 | — | — | CN | disclosed |
| EP-3510404-A1 | CHEMICAL PROBES OF LYSYL OXIDASE-LIKE 2 AND USES THEREOF | Pharmakea, Inc. (US) | 2019-07-17 | — | — | EP | disclosed |
| US-20190192697-A1 | CHEMICAL PROBES OF LYSYL OXIDASK-LIKE 2 AND USES THEREOF | PHARMAKEA, INC. | 2019-06-27 | — | — | US | disclosed |
| WO-2018048928-A1 | CHEMICAL PROBES OF LYSYL OXIDASE-LIKE 2 AND USES THEREOF | PHARMAKEA, INC. (US) | 2018-03-15 | — | — | WO | disclosed |
| EP-0069507-A2 | Hydrocarbon compositions containing heteroaromatic nitrogen compounds | EXXON RESEARCH AND ENGINEERING COMPANY (US) | 1983-01-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190192697-A1 | CHEMICAL PROBES OF LYSYL OXIDASK-LIKE 2 AND USES THEREOF | LOXL2, LOXL1, LOXL3 | KDM4E 3469/4885ALDH1A1 1508/4885GLA 482/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.